Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma

Autor:	Nina Shah, Ali Mojebi, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender Dhanda
Rok vydání:	2022
Předmět:	Receptors Chimeric Antigen Health Policy Antineoplastic Combined Chemotherapy Protocols Humans Multiple Myeloma Progression-Free Survival
Zdroj:	Journal of Comparative Effectiveness Research. 11:737-749
ISSN:	2042-6313 2042-6305 0336-1748
DOI:	10.2217/cer-2022-0045
Popis:	Aim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual patient-level data from the pivotal, phase II, single-arm KarMMa trial (NCT03361748) and aggregate-level data from MAMMOTH, the largest independent observational study of CC in heavily pretreated RRMM patients. Results: Ide-cel improved overall response rate (odds ratio: 5.30; 95% CI: 2.96–9.51), progression-free survival (hazard ratio: 0.50; 95% CI: 0.36–0.70) and overall survival (hazard ratio: 0.37; 95% CI: 0.25–0.56) versus CC. Conclusion: These results suggest ide-cel offers improvements in clinical outcomes relative to CC in this heavily pretreated RRMM population.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10dba4f23f3383b575a13406d0a78540 https://doi.org/10.2217/cer-2022-0045 Zobrazit plný text záznamu